IDC 002
Alternative Names: IDC-002Latest Information Update: 12 May 2022
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immune checkpoint protein inhibitors; PAUF protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ovarian cancer; Pancreatic cancer
Most Recent Events
- 05 May 2022 Early research in Ovarian cancer in Singapore (Parenteral) (Prestige Biopharma pipeline, May 2022)
- 05 May 2022 Early research in Pancreatic cancer in Singapore (Parenteral) (Prestige Biopharma pipeline, May 2022)
- 05 May 2022 Prestige BioPharma plans regulatory submission to EMA and US FDA for pancreatic cancer and ovarian cancer in 2026